Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
RegulatorySpikevaxPositive
AI Analysis
Summary
Genevant Sciences and Arbutus Biopharma announced a $2.25 billion global settlement with Moderna to resolve patent infringement claims related to unauthorized use of their LNP delivery technology in Moderna's COVID-19 vaccines including Spikevax.
Outcome Details
Global settlement resolving all U.S. and international enforcement actions regarding unauthorized use of LNP delivery technology in Moderna's COVID-19 vaccines
Importance:9/10
Sentiment:
0.85
patent_litigationsettlementlipid_nanoparticleCOVID-19licensing_dispute
Read the original article
Published by GlobeNewswire Pharma on March 3, 2026 9:15 PM